“…There is considerable evidence demonstrating abnormalities in the amygdala following chronic MAP use (Kim et al , 2011, London et al , 2004 which is likely to be at least partly responsible for the development of anxiety, stress, depression (Dawe et al , 2009, Goeldner et al , 2011, Morley et al , 2001, Thompson et al , 2004) and social cognitive deficits (Dawe et al, 2009, Volkow et al , 2011. Given that OT is known to stimulate oxytocinergic neurons in the amygdala (Carson et al, 2010c) and that the amygdala is partly responsible for the prosocial, antidepressant and anxiolytic properties of OT (Baumgartner et al, 2008, Debiec, 2005, Domes et al , 2007, Febo et al , 2005, Febo et al , 2009, it would be intriguing to speculate that the upregulation of OTRs in this regions, following chronic MAP administration, may be involved in the modulation of the behavioural consequences of chronic MAP use including depression, anxiety and social deficits. Interestingly, Thompson et al, (2007) strongly implicated the oxytocinergic system of the central medial amygdala in the prosocial effect of the drug MDMA ("ecstasy").…”